| Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (NCT05737485) | ReCode Therapeutics | 2023-02-18 |
| Montmorency Cherry Supplementation, Sleep, and Inflammation (NCT05700643) | Michigan State University | 2023-02-18 |
| A Study of [14C]IBI351 in Healthy Subjects (NCT05626179) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-18 |
| Biomarkers of ADHD Treatment Response (NCT05650775) | Boston Children's Hospital | 2023-02-17 |
| Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. (NCT05681273) | Chipscreen Biosciences, Ltd. | 2023-02-17 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (NCT05697003) | Respirent Pharmaceuticals Co Ltd. | 2023-02-17 |
| Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (NCT05427487) | ImmVirx Pty Ltd | 2023-02-17 |
| A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (NCT05076552) | Tachyon Therapeutics, Inc. | 2023-02-17 |
| A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease (NCT05681819) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-02-17 |
| Bioavailability Study to Compare Liquid vs Two Solid Formulations of IP2015 (NCT05728671) | Initiator Pharma | 2023-02-16 |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML (NCT05558124) | H. Lee Moffitt Cancer Center and Research Institute | 2023-02-16 |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab (NCT05319639) | Fujian Cancer Hospital | 2023-02-16 |
| Platelet Rich Plasma Uterine Infusion (NCT06621342) | University of Kansas Medical Center | 2023-02-16 |
| A Study of IBI351 in Healthy Subjects (NCT05688124) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-16 |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT05816499) | Shanghai Chest Hospital | 2023-02-16 |
| Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1 (NCT05614531) | Guangzhou Jiayin Biotech Ltd | 2023-02-16 |
| A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men (NCT05742919) | Novo Nordisk A/S | 2023-02-16 |
| A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia (NCT05655819) | David J. Cangemi | 2023-02-16 |
| A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants (NCT05638282) | Bristol-Myers Squibb | 2023-02-15 |
| A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer (NCT05683418) | Totus Medicines | 2023-02-15 |
| A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (NCT04808245) | German Cancer Research Center | 2023-02-15 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) (NCT05518188) | Elpida Therapeutics SPC | 2023-02-15 |
| Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers (NCT05734482) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2023-02-15 |
| Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects (NCT05699070) | Daewoong Pharmaceutical Co. LTD. | 2023-02-15 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (NCT05789342) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2023-02-15 |
| A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months (NCT05743881) | ModernaTX, Inc. | 2023-02-15 |
| A Food Effect Study of TS-142 in Healthy Subjects (NCT05707897) | Taisho Pharmaceutical Co., Ltd. | 2023-02-15 |
| Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma (NCT05738447) | West China Hospital | 2023-02-15 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects (NCT05701826) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-02-15 |
| A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (NCT05727644) | Novo Nordisk A/S | 2023-02-15 |
| Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease (NCT03992469) | Icahn School of Medicine at Mount Sinai | 2023-02-15 |
| AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) (NCT04859296) | University of California, Los Angeles | 2023-02-15 |
| PRE-I-SPY Phase I/Ib Oncology Platform Program (NCT05868226) | QuantumLeap Healthcare Collaborative | 2023-02-15 |
| A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors (NCT05764915) | Regor Pharmaceuticals Inc. | 2023-02-15 |
| Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis. (NCT05712538) | Arcturus Therapeutics, Inc. | 2023-02-15 |
| Atezolizumab for Idiopathic Pulmonary Fibrosis (NCT05515627) | Cedars-Sinai Medical Center | 2023-02-15 |
| Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (NCT05738850) | AbbVie | 2023-02-15 |
| Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer (NCT05721872) | Nazarbayev University | 2023-02-15 |
| Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases (NCT05477927) | Sichuan University | 2023-02-15 |
| Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (NCT06307249) | Lebanese University | 2023-02-15 |
| Oral Dexamethasone for the Management of Symptomatic Irreversible Pulpitis Without Performing Pulpotomy (NCT05761730) | May Samaha | 2023-02-15 |
| A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants (NCT05703841) | Janssen Research & Development, LLC | 2023-02-14 |
| Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) (NCT05683496) | ACELYRIN Inc. | 2023-02-14 |
| A Study of Idazoxan in Healthy Participants (NCT05727189) | Terran Biosciences Australia Pty Ltd | 2023-02-14 |
| Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy Subjects (NCT07679711) | The Affiliated Hospital of Qingdao University | 2023-02-14 |
| A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body (NCT05707403) | Boehringer Ingelheim | 2023-02-14 |
| A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML (NCT05641259) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2023-02-14 |
| Substance Balance Study of [14C]ZX-7101A in Healthy Adult Male Subjects in China (NCT05720091) | Nanjing Zenshine Pharmaceuticals | 2023-02-14 |
| ICVAX as a HIV Therapeutic DNA Vaccine (NCT06253533) | Immuno Cure Holding (HK) Limited | 2023-02-14 |
| Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution) (NCT05716763) | Unither Pharmaceuticals, France | 2023-02-14 |
| A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD (NCT05822908) | Vico Therapeutics B. V. | 2023-02-14 |
| Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors (NCT05614258) | Adagene Inc | 2023-02-13 |
| A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients (NCT05679388) | University of Chicago | 2023-02-13 |
| Superdonor FMT in Patients With Ulcerative Colitis (NCT05739864) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2023-02-13 |
| A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) (NCT05673460) | Merck Sharp & Dohme LLC | 2023-02-13 |
| Genotype-guided Treatment in Newly Diagnosed PTCL (NCT05675813) | Ruijin Hospital | 2023-02-13 |
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI (NCT05381038) | National University Hospital, Singapore | 2023-02-13 |
| A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL (NCT05515406) | Ono Pharmaceutical Co., Ltd. | 2023-02-13 |
| Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients (NCT07648940) | Zodiac Produtos Farmaceuticos S.A. | 2023-02-13 |
| A Phase I Study Of JS015 in Patients With Advanced Solid Tumors (NCT05770310) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-13 |
| The Safety and Tolerability of WS016 in Healthy Chinese Volunteers (NCT06281470) | Waterstone Pharmaceutical (Wuhan) Co., LTD. | 2023-02-13 |
| Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT05618327) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-13 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients (NCT05729074) | HK inno.N Corporation | 2023-02-13 |
| A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants (NCT06937411) | Eli Lilly and Company | 2023-02-13 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) (NCT05641324) | Anaveon AG | 2023-02-10 |
| Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT05739981) | Imunon | 2023-02-10 |
| A Study of LY3848575 in Healthy Participants (NCT05727072) | Eli Lilly and Company | 2023-02-10 |
| Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (NCT05676710) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-10 |
| Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients (NCT05848466) | Bio-Thera Solutions | 2023-02-10 |
| A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) (NCT05485753) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-02-10 |
| Beta-glucan and Fatigue in HSCT Survivors (NCT05524688) | University of Florida | 2023-02-10 |
| A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (NCT05668858) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-02-10 |
| Autologous Tumour Vaccine Trial (NCT05807035) | Vaxine Pty Ltd | 2023-02-10 |
| RAB001（LLP2A-Ale） in Healthy Subjects (NCT07545018) | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 2023-02-10 |
| A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration (NCT05456828) | Visara, Inc. | 2023-02-10 |
| Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients (NCT05636267) | Akeso | 2023-02-10 |
| PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 (NCT05737615) | Memorial Sloan Kettering Cancer Center | 2023-02-10 |
| Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer (NCT05633979) | M.D. Anderson Cancer Center | 2023-02-09 |
| Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (NCT05501054) | M.D. Anderson Cancer Center | 2023-02-09 |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer (NCT05664971) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-09 |
| DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan (NCT05947604) | Drugs for Neglected Diseases | 2023-02-09 |
| Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection. (NCT06291883) | Sheng-Teng Huang | 2023-02-09 |
| A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems (NCT05718648) | Boehringer Ingelheim | 2023-02-09 |
| Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects (NCT05659927) | Shanghai Mabgeek Biotech.Co.Ltd | 2023-02-09 |
| A Study of AK130 in Patients With Advanced Malignant Tumors (NCT05653284) | Akeso | 2023-02-09 |
| The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell) (NCT05769049) | Jiangsu Rec-Biotechnology Co., Ltd. | 2023-02-09 |
| Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma (NCT05565807) | Zhejiang ACEA Pharmaceutical Co. Ltd. | 2023-02-09 |
| A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects (NCT05525468) | Technoderma Medicines Inc. | 2023-02-08 |
| Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects (NCT05781906) | Hutchmed | 2023-02-08 |
| A Study of RD14-01 in Patients With Advanced Solid Tumors (NCT05748938) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2023-02-08 |
| Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors (NCT05714748) | West China Hospital | 2023-02-08 |
| An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief (NCT05845970) | Focus Consumer Healthcare | 2023-02-08 |
| Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2) (NCT05413473) | AHS Cancer Control Alberta | 2023-02-08 |
| A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) (NCT05656040) | Merck Sharp & Dohme LLC | 2023-02-08 |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (NCT05716295) | Medikine, Inc. | 2023-02-08 |
| A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab (NCT05304130) | GlaxoSmithKline | 2023-02-08 |
| Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets (NCT07508501) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-02-08 |
| Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors (NCT05707910) | West China Hospital | 2023-02-08 |
| A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer (NCT06266143) | Wuhan YZY Biopharma Co., Ltd. | 2023-02-08 |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (NCT05731271) | Suzhou Transcenta Therapeutics Co., Ltd. | 2023-02-08 |